Rapid in vivo assessment of drug efficacy against Mycobacterium tuberculosis using an improved firefly luciferase

• Published in: Journal of antimicrobial chemotherapy Vol. 68; no. 9; pp. 2118 - 2127
• Main Authors: Andreu, Nuria, Zelmer, Andrea, Sampson, Samantha L, Ikeh, Melanie, Bancroft, Gregory J, Schaible, Ulrich E, Wiles, Siouxsie, Robertson, Brian D
• Format: Journal Article
• Language: English
• Published: England Oxford Publishing Limited (England) 01.09.2013; Oxford University Press
• Subjects: Animals; Antitubercular Agents - administration & dosage; Bacteria; Bioluminescence; Disease Models, Animal; Drug Evaluation, Preclinical - methods; Enzymes; Female; Genes, Reporter; Luciferases, Firefly - analysis; Luciferases, Firefly - genetics; Luminescent Measurements; Medical treatment; Mice; Molecular Sequence Data; Mycobacterium tuberculosis; Mycobacterium tuberculosis - drug effects; Mycobacterium tuberculosis - genetics; Original Research; Rodents; Sequence Analysis, DNA; Tuberculosis; Tuberculosis - drug therapy; Tuberculosis - microbiology; Whole Body Imaging; drug testing; mouse model; bioluminescence; optical imaging
• ISSN: 0305-7453; 1460-2091
• DOI: 10.1093/jac/dkt155

In vivo experimentation is costly and time-consuming, and presents a major bottleneck in anti-tuberculosis drug development. Conventional methods rely on the enumeration of bacterial colonies, and it can take up to 4 weeks for Mycobacterium tuberculosis to grow on agar plates. Light produced by recombinant bacteria expressing luciferase enzymes can be used as a marker of bacterial load, and disease progression can be easily followed non-invasively in live animals by using the appropriate imaging equipment. The objective of this work was to develop a bioluminescence-based mouse model of tuberculosis to assess antibiotic efficacy against M. tuberculosis in vivo. We used an M. tuberculosis strain carrying a red-shifted derivative of the firefly luciferase gene (FFlucRT) to infect mice, and monitored disease progression in living animals by bioluminescence imaging before and after treatment with the frontline anti-tuberculosis drug isoniazid. The resulting images were analysed and the bioluminescence was correlated with bacterial counts. Using bioluminescence imaging we detected as few as 1.7 × 10(3) and 7.5 × 10(4) reporter bacteria ex vivo and in vivo, respectively, in the lungs of mice. A good correlation was found between bioluminescence and bacterial load in both cases. Furthermore, a marked reduction in luminescence was observed in living mice given isoniazid treatment. We have shown that an improved bioluminescent strain of M. tuberculosis can be visualized by non-invasive imaging in live mice during an acute, progressive infection and that this technique can be used to rapidly visualize and quantify the effect of antibiotic treatment. We believe that the model presented here will be of great benefit in early drug discovery as an easy and rapid way to identify active compounds in vivo.